| Title |
Sertraline versus other antidepressive agents for depression
|
|---|---|
| Published in |
Cochrane database of systematic reviews, April 2010
|
| DOI | 10.1002/14651858.cd006117.pub4 |
| Pubmed ID | |
| Authors |
Andrea Cipriani, Teresa La Ferla, Toshi A Furukawa, Alessandra Signoretti, Atsuo Nakagawa, Rachel Churchill, Hugh McGuire, Corrado Barbui |
| Abstract |
The National Institute for Health and Clinical Excellence clinical practice guideline on the treatment of depressive disorder recommended that selective serotonin reuptake inhibitors should be the first-line option when drug therapy is indicated for a depressive episode. Preliminary evidence suggested that sertraline might be slightly superior in terms of effectiveness. |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Saudi Arabia | 1 | 20% |
| Turkey | 1 | 20% |
| United States | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 60% |
| Scientists | 1 | 20% |
| Practitioners (doctors, other healthcare professionals) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 321 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | <1% |
| Brazil | 1 | <1% |
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 316 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 58 | 18% |
| Student > Master | 53 | 17% |
| Researcher | 34 | 11% |
| Student > Doctoral Student | 20 | 6% |
| Student > Ph. D. Student | 16 | 5% |
| Other | 45 | 14% |
| Unknown | 95 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 91 | 28% |
| Psychology | 27 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 24 | 7% |
| Nursing and Health Professions | 16 | 5% |
| Agricultural and Biological Sciences | 14 | 4% |
| Other | 40 | 12% |
| Unknown | 109 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2021.
All research outputs
#4,715,116
of 23,577,654 outputs
Outputs from Cochrane database of systematic reviews
#7,192
of 12,746 outputs
Outputs of similar age
#20,006
of 96,623 outputs
Outputs of similar age from Cochrane database of systematic reviews
#36
of 76 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 12,746 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 33.1. This one is in the 43rd percentile – i.e., 43% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 96,623 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 76 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.